EUVIMEDEUVIMED entdecken
Crossref

The topical azithromycin meibomian gland dysfunction survey: The effect of topical azithromycin on signs and symptoms of meibomian gland dysfunction

Ian Jarvis iD, Sara McCullough iD, John Jarvis

Ophthalmic and Physiological Optics · 2024

DOI: 10.1111/opo.13330 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ophthalmic and Physiological Optics, 2024. Verfasst von Ian Jarvis und 2 weiteren Autor:innen. Beteiligte Einrichtung: Jarvis Eyecare, Dundee, UK. Hauptthemen laut MEDLINE: Azithromycin, Meibomian Gland Dysfunction, Anti-Bacterial Agents, Ophthalmic Solutions. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The aim of this study was to assess the long‐term effects of topical azithromycin on signs, symptoms and self‐management of meibomian gland dysfunction (MGD).

Methods

Forty participants were assessed for MGD and its effect on the fluorescein tear break‐up time (FTBUT). Participants were treated with topical azithromycin twice daily for 2 weeks and then once daily for a further 2 weeks. One year after treatment, 31 participants completed a survey assessing pre‐ and post‐treatment effect on symptoms, lifestyle and self‐treatment methods.

Results

Following treatment, there was a significant reduction in MGD grading from a median of grade 2 to grade 0 ( z = 4.40, p < 0.0001) and an increase in FTBUT from a median of 3–8 s ( z = 4.75, p < 0.0001). One year afterwards, the survey showed a significant improvement in symptoms (sensitivity to light, grittiness, burning, blurred vision, all p < 0.03) and reduction in required self‐treatments (lid wipes, tear substitutes, both p < 0.03). There was also a reduced impact on lifestyle (reading, night driving, computer use and watching television, all p < 0.0001) and in all environmental conditions (all p < 0.0001).

Conclusions

This study confirms the positive effect of topical azithromycin on MGD and shows it has a long‐term impact on symptoms, self‐treatment methods and lifestyle. This has implications for both chair time and healthcare costs when managing patients with MGD. Pending further clinical trials in a larger population with different demographics, topical azithromycin should be considered by all eyecare practitioners as a viable pharmacological treatment when managing MGD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzithromycinMeibomian Gland DysfunctionAnti-Bacterial AgentsOphthalmic SolutionsMeibomian GlandsHumansFemaleMaleMiddle AgedAgedAdultTearsAdministration, TopicalSurveys and Questionnaires

Stichwörter der Autor:innen

dry eyemeibomian gland dysfunctiontopical azithromycin

Substanzen

AzithromycinAnti-Bacterial AgentsOphthalmic Solutions

Autor:innen und Institutionen

  • Jarvis Eyecare, Dundee, UK.
  • Centre for Optometry & Vision Science, School of Biomedical Sciences, Ulster University, Coleraine, UK.

ORCID-Profile: Ian Jarvis, Sara McCullough

Zitieren

APA

Jarvis, I., McCullough, S., & Jarvis, J. (2024). The topical azithromycin meibomian gland dysfunction survey: The effect of topical azithromycin on signs and symptoms of meibomian gland dysfunction. Ophthalmic and Physiological Optics. https://doi.org/10.1111/opo.13330

Vancouver

Jarvis I, McCullough S, Jarvis J. The topical azithromycin meibomian gland dysfunction survey: The effect of topical azithromycin on signs and symptoms of meibomian gland dysfunction. Ophthalmic and Physiological Optics. 2024. doi:10.1111/opo.13330

BibTeX
@article{Jarvis2024,
  author = {Jarvis, Ian and McCullough, Sara and Jarvis, John},
  title = {The topical azithromycin meibomian gland dysfunction survey: The effect of topical azithromycin on signs and symptoms of meibomian gland dysfunction},
  journal = {Ophthalmic and Physiological Optics},
  year = {2024},
  doi = {10.1111/opo.13330}
}
Kostenlos starten →